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Abstract 
Background: Characterization of PD-L1 expression within clinically/radiologically negative but microscopically 
tumor positive sentinel lymph nodes (SLN) is important to our understanding of the relevance of this immune check-
point pathway for adjuvant therapy.
Methods: Patients included had primary cutaneous melanoma, Breslow thickness of 2.01–4.0 or >4 mm with or 
without tumor ulceration (T3a, T3b, T4a, T4b). All patients had microscopically tumor positive SLN. Hematoxylin and 
eosin (H&E) staining was performed, followed by PD-L1 immunohistochemical (IHC) staining using a preliminary IHC 
assay with anti-PD-L1 antibody clone 22C3. The slides were separately evaluated by two pathologists (JY and CG). 
Samples containing metastatic melanoma lesions were scored separately for PD-L1 expression in intratumoral and 
peritumoral locations, by utilizing two scoring methods.
Results: Twenty-four patients where metastatic melanoma presence in the SLN was confirmed by H&E review of 
the cut sections were included in the final analysis of PD-L1 expression. SLN tumor size ranged from 1 to 2 mm. For 
three patients, the melanin content was too high to confidently assign a PD-L1 score. For the remaining 21 patients, 
all had some evidence of either intratumoral or peritumoral PD-L1 expression. The frequency of intratumoral tumor-
associated PD-L1 expression was: 0 % of tumor cells (3 pts, 14 %); <1 % (5 pts, 24 %); 1–10 % (6 pts, 29 %) and >10 % 
(7 pts, 33 %).
Conclusions: Tumor-associated PD-L1 expression is readily detectable within melanoma micrometastases in the 
SLN of the majority of patients. These results support the testing of a therapeutic role for PD1/PD-L1 inhibition in the 
adjuvant setting, targeting melanoma micrometastases.
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Background
PD-1 is an immune-inhibitory receptor belonging to 
CD28/CTLA4 receptor family that is expressed on acti-
vated T cells, B cells and monocytes [1, 2]. PD-1 is also 
expressed on T regulatory cells where it interacts with 
dendritic cells and NK T cells, and shown to be associated 
with anergy and tumor immune escape [3–5]. The role of 
PD-1 as a negative regulator of T cell activity is mediated 
through its interaction with its ligands PD-L1 and PD-L2 
(also known as B7-H1 and B7-H2 based on the similar-
ity to other B7 family molecules) that are expressed on 
immune cells and tumor cells [6]. PD-L1 is expressed on 
T and B cells, macrophages and dendritic cells [7]. PD-L1 
and PD-L2 are expressed on many human tumors includ-
ing melanoma, glioblastoma, non-small cell lung cancer 
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and urothelial, ovarian, breast, cervical, colon, pancreatic 
and gastric carcinoma [8–18]. PD-L1 has been impli-
cated in tumor immune escape from the host immune 
system and in mediating tumor anti-apoptotic activity 
[2, 19–21]. PD-1 ligand 1 and 2 (PD-Ls) expressed on 
antigen-presenting cells have been shown to indirectly 
induce T cell anergy or exhaustion via PD-1 on T cells, 
whereas PD-L1 expressed on peripheral tissues directly 
suppresses self-reactive lymphocytes [22, 23]. PD-Ls 
expressed on tumors regulate the generation of adaptive 
regulatory T cells resulting in tumor-induced immune 
suppression [5], including the suppression of the effec-
tor function of CD8+ T cells [21]. Interestingly, a sig-
nificant inverse correlation was observed between PD-L1 
expression and the intraepithelial CD8+ T lymphocyte 
count, suggesting that PD-L1 on tumor cells directly sup-
presses antitumor CD8+ T cells [9]. PD-1 blockade has 
been shown to enhance the expansion and functional 
capacity of human melanoma antigen specific cytotoxic 
T cells [24]. Clinically, higher expression levels of PD-L1 
on tumors have been shown to correlate with poor prog-
nosis in several malignant tumors including melanoma, 
esophagus, kidney, lung, and brain, pancreatic, ovar-
ian and head and neck [8, 9, 12, 16, 25, 26]. These data 
illustrate a central role for the PD-1/PD-L1 axis in tumor 
immune escape and have led to the clinical targeting of 
PD-1 and PD-L1 as an antitumor strategy.
Pembrolizumab and nivolumab, both of which tar-
get PD-1, have been approved for the treatment of 
metastatic melanoma. Approval of pembrolizumab was 
granted based on data from a cohort of a phase I trial 
(KEYNOTE-002) in which 411 patients with advanced 
melanoma who were refractory to ipilimumab or were 
ipilimumab naive received pembrolizumab at 2 or 10 mg/
kg every 3  weeks or 10  mg/kg every 2  weeks [27, 28]. 
Overall response rates were 40 and 28 % in ipilimumab-
naive and ipilimumab-refractory treatment arms, respec-
tively. In addition, response rates and progression-free 
survival were significantly higher in patients with high 
PD-L1 tumor expression compared with patients who 
were considered PD-L1 negative [29]. In December 2014, 
nivolumab became the second monoclonal antibody tar-
geting the PD-1 receptor to be approved by FDA for the 
treatment of patients with unresectable or metastatic 
melanoma and disease progression following ipilimumab 
and a BRAF inhibitor [30]. Approval for nivolumab was 
based on results from the first 120 patients enrolled in 
a phase III trial (CheckMate 037) testing nivolumab 
versus either dacarbazine or carboplatin/paclitaxel in 
patients with metastatic melanoma who progressed 
on or after anti-CTLA-4 therapy and a BRAF inhibi-
tor (if BRAF V600 mutation positive). The overall tumor 
response rates were 32 and 11  % in favor of nivolumab 
[31]. The use of nivolumab in previously untreated meta-
static patients has also shown excellent activity; objective 
response rate of 40.0 % as compared to 13.9 % in the dac-
arbazine group [32].
The significant clinical activity of anti-PD1 antibodies 
has supported their planned testing as adjuvant ther-
apy in patients with operable melanoma at high risk for 
relapse and death from melanoma. Adjuvant therapy 
targets micrometastatic disease which is the source of 
future mortality from melanoma recurrence and presents 
an opportunity for curing this disease. We hypothesized 
that micrometastatic tumors that are the source of future 
melanoma relapse in high risk patients express PD-L1 
making them susceptible to PD1/PD-L1 therapeutic 
blockade. Characterization of PD-L1 expression within 
clinically/radiologically negative but microscopically 
tumor positive sentinel lymph nodes (SLN) is important 
to our understanding of the relevance of this immune 
checkpoint pathway for adjuvant therapy. In this report, 
we present data which shows that tumor-associated 
PD-L1 expression is readily detectable within melanoma 
micrometastases in the SLN.
Methods
Patients
Twenty-four patients with primary cutaneous melanoma 
were included in this study. All patients had a primary 
tumor Breslow thickness of 2.01–4.00 mm without (T3a) 
or with ulceration (T3b), or >4 mm without (T4a) or with 
ulceration (T4b). Patients had known microscopically 
tumor positive SLN detected during standard SLN biopsy 
procedures. All patients provided a written informed 
consent. Table  1 summarizes patient demographics and 
baseline disease characteristics.
Procedures
Cut sections (5 µm) were obtained from formalin-fixed, 
paraffin-embedded (FFPE) SLN tissue from patients 
enrolled on this study. Slides were first stained with 
haematoxylin and eosin. PD-L1 immunostaining was 
performed using a preliminary immunohistochemis-
try (IHC) assay with anti-PD-L1 antibody clone 22C3. 
Slides from two patients were also stained using an anti-
HMB45/MelA protocol to better ascertain the presence 
and/or localization of melanoma lesions in the tissue in 
order to facilitate interpretation of the PD-L1 staining in 
those samples. All staining was performed on Dako auto-
stainers at Merck Research Laboratories, Palo Alto, CA. 
The anti-PD-L1 antibody clone 22C3 is a mouse anti-
human PD-L1 IgG1k generated through murine immuni-
zation with a fusion protein containing the human extra 
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cellular domain of PD-L1 and subsequent hybridoma for-
mation [33].
The slides were separately evaluated by two patholo-
gists. Samples containing metastatic melanoma lesions 
were scored separately for PD-L1 expression in intratu-
moral (including along tumor periphery but with clear 
tumor cell labeling) and peritumoral (expression exter-
nal to tumor nodule in immediately surrounding tissue) 
locations. PD-L1 positivity was defined as partial or com-
plete membrane staining of a tumor cell using the 22C3 
antibody [33]. Two scoring methods were utilized: (1) 
semi-quantitative scoring method—samples containing 
metastatic melanoma lesions were scored separately for 
PD-L1 expression in intratumoral (including along tumor 
periphery but with clear tumor cell labeling) and peritu-
moral (expression external to tumor nodule in immedi-
ately surrounding tissue; immune cells) locations. For 
intratumoral signals, attempts were made to classify the 
expression as tumor cell associated (indicated by the let-
ter “T”), non-tumor cell associated (indicated by the let-
ters “NT”), or both (indicated by “T/NT”). Scores were 
assigned using a 0–5 semiquantitative scale assessing 
prevalence of positive cells where 0, negative; 1, mini-
mal or rare; 2, low; 3, moderate; 4, high; and 5, very high. 
Samples where melanin content was too high to confi-
dently assign a PD-L1 score were specifically noted. (2) 
Percentage estimates: scores at the low end were given a 
score of 0 % of tumor cells, <1, 1, and 3 % (roughly indi-
cates >1 % but <5 %). Scores at the high end were given in 
10 % increments.
Statistical analysis
Descriptive statistics were used to tabulate and present 
the study findings.
Results
Twenty-four patients where metastatic melanoma pres-
ence in the SLN was confirmed by H&E review of the 
cut sections were included in the final analysis of PD-L1 
expression. Table  1 summarizes patient demograph-
ics and disease characteristics. Table  2 summarizes the 
results of tumor associated PD-L1 expression. Three 
patient samples were noted to have high melanin content 
where it was difficult to assign a PD-L1 expression score.
Of the remaining 21 patient samples, 13 (62 %) showed 
PD-L1 positivity defined as partial or complete mem-
brane staining in ≥1  % (range 1–90  %) of tumor cells 
using the 22C3 antibody. The majority of patient samples 
(20 samples; 95 %) showed some degree of intratumoral 
or peritumoral PD-L1 expression. Table  3 presents the 
frequency of tumor-associated PD-L1 expression by the 
percentage of expression. Among patient samples that 
were considered PD-L1 positive, more than half were 
scored at >10 %. Figure 1 shows examples of SLN mela-
noma sample intratumoral PD-L1 immunohistochemi-
cal staining, both positive (A) and negative (B). Finally, 
we attempted to score the non-tumor (lymphoid tissue) 
associated PD-L1 expression in the 24 patient SLN sam-
ples included in this study. PD-L1 expression in these 
areas was classified as (1) expression by histiocytes in the 
sinuses of the node and (2) expression observed in non-
sinus lymphoid tissue with morphologic characteristics 
consistent with antigen presenting cell populations (den-
dritic cells and macrophages). Table 4 summarizes these 
observations.
Results and discussion
In this study, we have reported that melanoma patients 
with SLN micrometastases detected by SLN biopsy dem-
onstrate evidence of tumor associated PD-L1 expression. 
The majority of patients were found to have tumor asso-
ciated PD-L1 expression estimated by two scoring meth-
ods, including the percentage estimates method utilized 
in prior studies in patients with metastatic melanoma 
[34]. Inhibition of the PD-1/PD-L1 axis has emerged as 
an important immune checkpoint therapeutic strategy 
with unprecedented clinical responses seen in patients 
with metastatic melanoma. Efforts are underway to test 
anti-PD1 monoclonal antibodies as adjuvant therapy in 
patients with operable melanoma who continue to carry 
a high risk of recurrence and death after surgery. In these 
patients, residual micrometastatic disease is expected to 
be the source of future melanoma relapse. For patients 
with AJCC stages IIB-C/III/IV, melanoma carries a high 
Table 1 Patient demographics and  baseline disease char-
acteristics (N = 24 patients)
ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on 
Cancer
Variable No. of patients (%)
Age, years; median (range) 58 (18–75)
Cutaneous primary 24 (100)
Gender
 Female 12 (50)
 Male 12 (50)
Performance status (ECOG)
 0 18 (75)
 1 6 (25)
AJCC stage
 IIIA 5 (21)
 IIIB 16 (67)
 IIIC 3 (12)
Ulceration of primary
 Yes 18 (75)
 No 6 (25)
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risk for recurrence and death from melanoma with surgi-
cal management alone [35–38]. Systemic adjuvant ther-
apy that targets melanoma micrometastases is indicated 
postoperatively where it may provide the greatest oppor-
tunity for cure before relapse into advanced inoperable 
stages. Multiple systemic therapeutic agents have been 
tested as adjuvant therapy for melanoma with durable 
benefits seen only with high dose interferon-alfa (HDI) to 
date [39]. CTLA4-blockade with ipilimumab is currently 
being tested in the adjuvant EORTC 18071 trial (stage III; 
compared to placebo) and U.S. Intergroup E1609 (stage 
III and IV; compared to HDI). Ongoing adjuvant tri-
als are also targeting patients with BRAF mutant mela-
noma including vemurafenib (BRIM-8) and dabrafenib/
trametinib (COMBI-AD). Adjuvant trials involving PD1-
blockade are expected to be activated in the second quar-
ter of 2015. In this study, we have characterized PD-L1 
expression within clinically/radiologically negative but 
microscopically tumor positive SLN, which may be 
important to our understanding of the relevance of this 
immune checkpoint pathway for adjuvant therapy.
The findings of this study further support the investiga-
tion of PD-1/PD-L1 blockade in the adjuvant setting in 
melanoma patients with high risk for relapse.
Previous studies have shown that increased tumor asso-
ciated expression of PD-L1 is associated with a higher 
likelihood of clinical response to PD-1/PD-L1 blockade 
Table 2 Tumor associated PD-L1 expression
a Very few tumor cells. In one region where a few tumor cells were present, a dense area of PD-L1 positivity was present directly adjacent but was impossible to say if 
all were non-tumor; this is interpreted as most likely
Patient with SLN+ (N = 24) Tumor associated expression
Semi-quantitative scoring Percentage estimates—tumor
PD-L1 score—tumor PD-L1—peritumoral
1 1 T, very weak 1 3
2 4, predominantly T, peripheral 1 40
3 Melanin confounds 2 NA
4 0 2 (adjacent subcapsular sinus) 0
5 4 T/NT 2 30
6 2, predominantly NT 3 3
7 0 3 (adjacent subcapsular sinus) 0
8 2.5, predominantly NT 3 10
9 4.5, predominantly T, weak 2 (adjacent sinus) 50
10 Melanin confounds 0 NA
11 1 T 2.5 <1
12 0a 2 0
13 1 T 1 <1
14 2.5 NT 2 10
15 2 predominantly NT 3 3
16 1 T 2 1
17 Melanin confounds 0 NA
18 1 1 <1
19 1 NT 2.5 <1
20 2T?, melanin confounds 2 <1
21 4, predominantly T, peripheral 3.5 40
22 5, predominantly T 2 90
23 4 0 40
24 4.5 T/NT 0 70
Table 3 The frequency of tumor-associated PD-L1 expres-
sion by  percentage of  expression (excluding samples 
where melanin content was too high to confidently assign 
a PD-L1 score; N = 21)
Percentage esti-
mates
No. of patients 
(N = 21)
Percentage of patient 
(N = 21)
0 3 14
<1 5 24
1–10 6 29
>10 7 33
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[40–42]. Kefford et  al., reported that melanoma patients 
receiving pembrolizumab in the phase I KEYNOTE-001 
trial had differential clinical responses to treatment based 
on the baseline tumor PD-L1 expression pattern [34]. 
PD-L1 positivity in pre-treatment biopsies was defined 
as partial or complete membrane staining in ≥1  % of 
tumor cells using the 22C3 antibody [34]. Patients with 
PD-L1 positive tumors had a 49  % overall response rate 
(ORR) as compared to 13  % in those with PD-L1 nega-
tive tumors. In the phase I study that tested multiple 
doses of nivolumab in advanced melanoma, an explora-
tory analysis to investigate tumor PD-L1 expression and 
its association with treatment response was also under-
taken [43]. PD-L1 positivity was defined as tumor mem-
brane staining with any intensity and with cut-off values 
of 1 and 5 %. ORR was superior in patients with a PD-L1 
positive status. In the 1 % cutoff analysis, 35 % of patients 
considered PD-L1 positive had an objective response ver-
sus 13 % in PD-L1 negative. The ORR increased (44 %) in 
PD-L1 positive patients by increasing the cutoff to 5  % 
with no change in the ORR in the PD-L1 negative group. 
Overall survival (OS) in PD-L1 positive patients was 
25 months as compared to 12 months in PD-L1 negative 
at 1 % cutoff [43]. By increasing the cutoff to 5 %, median 
OS was not reached in the PD-L1 positive cohort as com-
pared to 13  months in PD-L1 negative. Similarly, PFS 
was 9 months in PD-L1 positive patients as compared to 
2 months in PD-L1 negative, at both 1 and 5 % cutoff [43]. 
Similar findings have been reported in other tumor types 
in patients treated with anit-PD1 antibodies. For exam-
ple, patients with non-small cell lung cancer (NSCLC) 
receiving nivolumab in a phase I clinical trial also showed 
correlation between clinical efficacy and tumor PD-L1 
expression [44]. PD-L1 negative tumors showed no objec-
tive responses to nivolumab as compared to a 50 % ORR 
in patients with PD-L1 positive status. PFS at 24  weeks 
was 70 % and 1-year OS of 80 % in PD-L1 positive patients 
as compared to 57 and 71  % in PD-L1 negative patients 
respectively [44]. The extent of PD-L1 expression was also 
found to correlate with ORR in a recent study of pem-
brolizumab in NSCLC with shorter progression-free and 
overall survival among patients with low tumor expres-
sion of PD-L1 [42]. Recently, PD-L1 expression in the 
immune infiltrate in the tumor has also been found to 
be associated with response to PD-1 pathway blockade 
therapy [45]. Interestingly, tumor PD-L1 negative sta-
tus although it carries a lower likelihood of response to 
anti-PD1 antibodies, it does not preclude response and 
it is widely understood that the clinical utility of PD-L1 
tumor expression requires refinement. However, these 
observations in patients with metastatic melanoma and 
other malignancies, support our hypothesis that micro-
metastatic tumors that are the source of future melanoma 
relapse in high risk patients express PD-L1 making them 
susceptible to PD1/PD-L1 therapeutic blockade.
Scoring of non-tumor associated PD-L1 expression in 
in the SLN was complicated by the fact that historical 
PD-L1 scoring has consistently centered on expression 
localized to and immediately surrounding tumor tis-
sue. Normal or reactive lymphoid tissue is not typically 
included in scoring, so no experiential base exists for this 
type of analysis. In order to try to provide maximal infor-
mation however, attempts were made to provide scores 
of PD-L1 expression in non-tumor infiltrated regions of 
lymph nodes where metastatic lesions were identified. 
PD-L1 expression in these areas could be classified as 
falling into two basic categories: (1) expression by his-
tiocytes in the sinuses of the node and (2) expression 
observed in non-sinus lymphoid tissue with morphologic 
characteristics consistent with antigen presenting cell 
populations (dendritic cells and macrophages). Each of 
these categories was scored separately using a 0–5 semi-
quantitative system, focused on signal prevalence. Given 
Fig. 1 Examples of sentinel lymph node melanoma sample intratu-
moral PD-L1 immunohistochemical staining, including positive for 
PD-L1 expression (brown chromogen) (a) and negative (b). The arrows 
point to representative areas of membranous staining interpreted as 
tumor cell expression. The scale bar represents 100 μm
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the very different representation of tissue from sample 
to sample and the lack of historical experience with this 
type of non-tumor associated scoring by the evaluating 
pathologists, this data should be interpreted as extremely 
exploratory, and not suitable for drawing conclusions.
Conclusions
In conclusion, tumor-associated PD-L1 expression is 
readily detectable within melanoma micrometastases in 
the SLN of the majority of patients included in this study. 
These results support the testing of a therapeutic role 
for PD1/PD-L1 inhibition in the adjuvant therapy set-
ting, targeting melanoma micrometastases. The testing of 
PD-L1 expression as a predictive biomarker for therapeu-
tic benefit from anti-PD1 therapy is also warranted and 
to the best of our knowledge is planned in the context of 
ongoing adjuvant trials.
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